av Øivind Enger | mar 4, 2022 | News
Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum. The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia...
av Øivind Enger | jun 8, 2021 | News
BerGenBio announces the the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for bemcentinib in combination with and anti-PD-(L)1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer (NSCLC)...
av Øivind Enger | mai 18, 2021 | News
APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The proceeds from the investment round will be used to conduct a Phase-2 study in sarcoma. The study will be initiated and...
av Øivind Enger | mai 11, 2021 | News
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...
av Øivind Enger | mai 5, 2021 | News
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...